Amarin (AMRN)
(Delayed Data from NSDQ)
$0.87 USD
+0.02 (2.94%)
Updated May 31, 2024 04:00 PM ET
After-Market: $0.87 +0.01 (0.58%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Brokerage Reports
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 241 - 260 ( 359 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
We are dropping coverage due to analyst departure
Provider: WEDBUSH SECURITIES INC.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Drug Launch Weekly Retail Sales Tracker - Week Ending March 15; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Watching Scripts and Waiting on Q1 Sales Data for Early Read on Vascepa Launch; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Expect Focus on Vascepa Launch and ANCHOR sNDA Filing During Upcoming Earnings Call; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Patent Update; Focus on Upcoming Commercial Launch;
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Shifting Focus to Upcoming Self-Commercialization as NCE is Delayed Again; Reiterate NEUTRAL and Lowering FV to $10 from $15
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of December 16
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.